## During negative regulation of the human papillomaviru protein can displace Sp1 from a proximal promoter elem

Nucleic Acids Research 20, 251-256 DOI: 10.1093/nar/20.2.251

**Citation Report** 

#	Article	IF	CITATIONS
1	Activation of human papillomavirus type 18 E6–E7 oncogene expression by transcription factor Sp1. Nucleic Acids Research, 1992, 20, 6701-6706.	6.5	66
2	The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Research, 1993, 27, 133-145.	1.1	155
3	A novel cis-stimulatory element maps to the 5' portion of the human papillomavirus type 18 upstream regulatory region and is functionally dependent on a sequence-aberrant Sp1 binding site. Journal of General Virology, 1993, 74, 281-286.	1.3	22
4	The E6/E7 promoter of extrachromosomal HPV16 DNA in cervical cancers escapes from cellular repression by mutation of target sequences for YY1 EMBO Journal, 1994, 13, 1460-1466.	3.5	148
5	Primer-Directed Sequencing of Human Papillomavirus Types. Current Topics in Microbiology and Immunology, 1994, 186, 13-31.	0.7	79
6	Transcriptional Control and Cell Type Specificity of HPV Gene Expression. Archives of Dermatology, 1994, 130, 210.	1.7	36
7	Cellular control of human papillomavirus oncogene transcription. Molecular Carcinogenesis, 1994, 10, 134-141.	1.3	59
8	Multiple Regulatory Elements Control the Basal Promoter Activity of the Human α4 Integrin Gene. DNA and Cell Biology, 1994, 13, 1071-1085.	0.9	22
9	The Structure, Function, and Regulation of Papillomaviral Genes in Infection and Cervical Cancer. Advances in Virus Research, 1994, 44, 305-356.	0.9	69
10	The Interaction between Human Papillomavirus Type 16 El and E2 Proteins is Blocked by An Antibody to the N-Terminal Region of E2. FEBS Journal, 1995, 229, 517-525.	0.2	35
11	Binding of the transcription factor, Sp1, to non-target sites in DNA modified by benzo[a]pyrene diol epoxide. Carcinogenesis, 1995, 16, 975-983.	1.3	47
12	Control of HPV 18 DNA replication by cellular and viral transcription factors. Nucleic Acids Research, 1995, 23, 4777-4784.	6.5	60
13	THE GENETIC PROGRAM OF GENITAL HUMAN PAPILLOMAVIRUSES IN INFECTION AND CANCER. Obstetrics and Gynecology Clinics of North America, 1996, 23, 735-758.	0.7	32
14	Letter to the editor: Functional characterization of naturally occurring mutants of human papillomavirus type 16 with large deletions in the non-coding region. , 1996, 68, 265-269.		5
15	A possible role for human papillomaviruses in head and neck cancer. Cancer and Metastasis Reviews, 1996, 15, 91-112.	2.7	78
16	DNA Binding and Bending by the Human Papillomavirus Type 16 E2 Protein. Journal of Biological Chemistry, 1997, 272, 8236-8242.	1.6	61
17	The Rat Growth Hormone and Human Cellular Retinol Binding Protein 1 Genes Share Homologous NF1-Like Binding Sites That Exert Either Positive or Negative Influences on Gene ExpressionIn Vitro. DNA and Cell Biology, 1997, 16, 951-967.	0.9	16
18	Identification of cis-regulatory elements in the upstream regulatory region of human papillomavirus type 59. Virus Research, 1997, 47, 155-166.	1.1	3

#	Article	IF	CITATIONS
19	Oct-1, silencer sequence, and GC box regulate thyroid hormone receptor β1 promoter. Molecular and Cellular Endocrinology, 1997, 130, 153-165.	1.6	9
20	Regulatory elements in the minimal promoter region of the mouse Xist gene. Gene, 1997, 203, 159-168.	1.0	29
21	Guanosine 3',5'-bis(diphosphate) (ppGpp)-Dependent Inhibition of Transcription from Stringently Controlled Escherichia Coli Promoters can be Explained by an Altered Initiation Pathway that Traps RNA Polymerase. FEBS Journal, 1997, 247, 990-999.	0.2	26
22	The Early HPV16 Proteins Can Regulate mRNA Levels of Cell Cycle Genes in Human Cervical Carcinoma Cells by p53-Independent Mechanisms. Virology, 1998, 244, 97-107.	1.1	13
23	Papillomavirus E2 induces p53-independent apoptosis in HeLa cells. Oncogene, 1999, 18, 4538-4545.	2.6	80
24	The integration of HPV-18 DNA in cervical carcinoma. Journal of Clinical Pathology, 1999, 52, 275-282.	2.1	88
25	Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21CIP-dependent pathways. EMBO Journal, 2000, 19, 5762-5771.	3.5	184
26	EGF stimulates gastrin promoter through activation of Sp1 kinase activity. American Journal of Physiology - Cell Physiology, 2000, 278, C697-C708.	2.1	72
27	Mechanisms of Human Papillomavirus E2-Mediated Repression of Viral Oncogene Expression and Cervical Cancer Cell Growth Inhibition. Journal of Virology, 2000, 74, 3752-3760.	1.5	94
28	Adeno-Associated Virus Major Rep78 Protein Disrupts Binding of TATA-Binding Protein to the p97 Promoter of Human Papillomavirus Type 16. Journal of Virology, 2000, 74, 2459-2465.	1.5	24
29	Intratype HPV16 sequence variation within LCR of isolates from asymptomatic carriers and cervical cancers. Journal of Clinical Virology, 2001, 23, 65-77.	1.6	28
30	Contributions in the domain of cancer research: Review¶Human papillomaviruses and their role in cervical cancer. Cellular and Molecular Life Sciences, 2001, 58, 1923-1942.	2.4	84
31	Orientation of a Novel DNA Binding Site Affects Human Papillomavirus-Mediated Transcription and Replication. Journal of Virology, 2001, 75, 1722-1735.	1.5	11
32	The E8 Domain Confers a Novel Long-Distance Transcriptional Repression Activity on the E8^E2C Protein of High-Risk Human Papillomavirus Type 31. Journal of Virology, 2001, 75, 4139-4149.	1.5	52
33	A Novel Silencer Element in the Bovine Papillomavirus Type 4 Promoter Represses the Transcriptional Response to Papillomavirus E2 Protein. Journal of Virology, 2001, 75, 2829-2838.	1.5	13
34	Human TATA Binding Protein Inhibits Human Papillomavirus Type 11 DNA Replication by Antagonizing E1-E2 Protein Complex Formation on the Viral Origin of Replication. Journal of Virology, 2002, 76, 5014-5023.	1.5	20
35	Regulation of human papillomavirus gene expression in the vegetative life cycle. Perspectives in Medical Virology, 2002, 8, 31-51.	0.1	4
36	Cooperative Activation of Human Papillomavirus Type 8 Gene Expression by the E2 Protein and the Cellular Coactivator p300. Journal of Virology, 2002, 76, 11042-11053.	1.5	45

#	Article	IF	CITATIONS
37	Molecular evolution of ribosomal intergenic spacers inOdontophrynus americanus2nand 4n(Amphibia: Anura). Genome, 2002, 45, 71-81.	0.9	4
38	Comparison of the Structure and DNA-binding Properties of the E2 Proteins from an Oncogenic and a Non-oncogenic Human Papillomavirus. Journal of Molecular Biology, 2003, 334, 979-991.	2.0	38
39	Human Papillomavirus Type 16 E2 Protein Has No Effect on Transcription from Episomal Viral DNA. Journal of Virology, 2003, 77, 2021-2028.	1.5	105
40	Transcriptome signature of irreversible senescence in human papillomavirus-positive cervical cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7093-7098.	3.3	77
41	Genetic and Biochemical Analysis of cis Regulatory Elements within the Keratinocyte Enhancer Region of the Human Papillomavirus Type 31 Upstream Regulatory Region during Different Stages of the Viral Life Cycle. Journal of Virology, 2004, 78, 612-629.	1.5	23
42	The 3' region of Human Papillomavirus type 16 early mRNAs decrease expression. BMC Infectious Diseases, 2005, 5, 83.	1.3	11
43	Gene Program Signatures for Papillomavirus E2-Mediated Senescence in Cervical Cancer Cells. , 2005, , 69-88.		0
44	Nucleo-cytoplasmic Shuttling of High Risk Human Papillomavirus E2 Proteins Induces Apoptosis. Journal of Biological Chemistry, 2005, 280, 36088-36098.	1.6	65
45	The Human DEK Proto-Oncogene Is a Senescence Inhibitor and an Upregulated Target of High-Risk Human Papillomavirus E7. Journal of Virology, 2005, 79, 14309-14317.	1.5	109
46	Induction of the Human Papillomavirus Type 31 Late Promoter Requires Differentiation but Not DNA Amplification. Journal of Virology, 2005, 79, 4918-4926.	1.5	47
47	Variant Upstream Regulatory Region Sequences Differentially Regulate Human Papillomavirus Type 16 DNA Replication throughout the Viral Life Cycle. Journal of Virology, 2005, 79, 5914-5922.	1.5	52
48	Cervical Cancer and Human Papillomaviruses: Inactivation of Retinoblastoma and Other Tumor Suppressor Pathways. Current Molecular Medicine, 2006, 6, 795-808.	0.6	14
49	Development of anticancer gene vaccine interact with human papillomavirus oncoprotein inhibition. International Journal of Gynecological Cancer, 2006, 16, 270-276.	1.2	4
50	Repression of HPV16 early region transcription by the E2 protein. Virology, 2006, 351, 29-41.	1.1	55
51	Brd4 Is Required for E2-Mediated Transcriptional Activation but Not Genome Partitioning of All Papillomaviruses. Journal of Virology, 2006, 80, 9530-9543.	1.5	159
52	Diffusible VP22–E2 Protein Kills Bystander Cells and Offers a Route for Cervical Cancer Gene Therapy. Human Gene Therapy, 2006, 17, 147-157.	1.4	16
53	The E8 repression domain can replace the E2 transactivation domain for growth inhibition of HeLa cells by papillomavirus E2 proteins. International Journal of Cancer, 2007, 121, 2284-2292.	2.3	24
54	Expression of the HPV11 E2 gene in transgenic mice does not result in alterations of the phenotypic pattern. Transgenic Research, 2008, 17, 1-8.	1.3	9

#	Article	IF	CITATIONS
55	Search for cellular partners of human papillomavirus type 16 E2 protein. Archives of Virology, 2008, 153, 983-990.	0.9	17
56	E2 and the co-activator p300 can cooperate in activation of the human papillomavirus type 16 early promoter. Virology, 2008, 377, 151-159.	1.1	23
57	Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs). Virology, 2008, 378, 329-338.	1.1	28
58	Functional Mapping of the Human Papillomavirus Type 16 E1 Cistron. Journal of Virology, 2008, 82, 10724-10734.	1.5	26
59	Methylation status of the long control region of HPV 16 in clinical cervical specimens. Molecular Medicine Reports, 0, , .	1.1	9
60	Gene silencing of HPV16 E6/E7 induced by promoter-targeting siRNA in SiHa cells. British Journal of Cancer, 2009, 101, 1798-1804.	2.9	31
61	Cell-type specific transcriptional activities among different papillomavirus long control regions and their regulation by E2. Virology, 2009, 395, 161-171.	1.1	23
62	Interaction of the Papillomavirus E8â^§E2C Protein with the Cellular CHD6 Protein Contributes to Transcriptional Repression. Journal of Virology, 2010, 84, 9505-9515.	1.5	21
63	Thermodynamics of Cooperative DNA Recognition at a Replication Origin and Transcription Regulatory Site. Biochemistry, 2010, 49, 10277-10286.	1.2	8
64	Papillomavirus interaction with cellular chromatin. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2010, 1799, 192-199.	0.9	37
65	Abrogation of the Brd4-Positive Transcription Elongation Factor b Complex by Papillomavirus E2 Protein Contributes to Viral Oncogene Repression. Journal of Virology, 2010, 84, 76-87.	1.5	60
66	Differential expression of cellular microRNAs in HPV 11, -16, and -45 transfected cells. Biochemical and Biophysical Research Communications, 2011, 412, 20-25.	1.0	22
67	Regulation of human papillomavirus type 16 early gene expression in trophoblastic and cervical cells. Virology, 2011, 412, 146-155.	1.1	14
68	The use of a human papillomavirus 18 promoter for tissue-specific expression in cervical carcinoma cells. Cellular and Molecular Biology Letters, 2011, 16, 477-92.	2.7	7
69	HPV16 E2 could act as down-regulator in cellular genes implicated in apoptosis, proliferation and cell differentiation. Virology Journal, 2011, 8, 247.	1.4	23
70	Productive Lifecycle of Human Papillomaviruses that Depends Upon Squamous Epithelial Differentiation. Frontiers in Microbiology, 2012, 3, 152.	1.5	95
71	Site-directed mutagenesis of human papillomavirus 18 promoter elements and tissue-specific expression in cervical carcinoma cells. Virus Genes, 2012, 44, 395-402.	0.7	1
72	Regulatory elements in the viral genome. Virology, 2013, 445, 197-204.	1.1	92

#	Article	IF	CITATIONS
73	Current Understanding of the Role of the Brd4 Protein in the Papillomavirus Lifecycle. Viruses, 2013, 5, 1374-1394.	1.5	38
74	Tumourigenesis Driven by the Human Papillomavirus Type 16 Asian-American E6 Variant in a Three-Dimensional Keratinocyte Model. PLoS ONE, 2014, 9, e101540.	1.1	26
75	CCCTC-Binding Factor Recruitment to the Early Region of the Human Papillomavirus 18 Genome Regulates Viral Oncogene Expression. Journal of Virology, 2015, 89, 4770-4785.	1.5	58
76	The Route to HPV-Associated Neoplastic Transformation: A Review of the Literature. Critical Reviews in Eukaryotic Gene Expression, 2016, 26, 27-39.	0.4	10
77	Genetic variations in the DNA replication origins of human papillomavirus family correlate with their oncogenic potential. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 979-990.	1.1	7
78	Identification of C-quadruplex forming sequences in three manatee papillomaviruses. PLoS ONE, 2018, 13, e0195625.	1.1	22
79	Human Papillomavirus Infection in Head and Neck Squamous Cell Carcinomas: Transcriptional Triggers and Changed Disease Patterns. Frontiers in Cellular and Infection Microbiology, 2020, 10, 537650.	1.8	22
80	Human Papillomavirus 16 (HPV16) E2 Repression of TWIST1 Transcription Is a Potential Mediator of HPV16 Cancer Outcomes. MSphere, 2020, 5, .	1.3	12
81	Evolution of Papillomaviruses. Current Topics in Microbiology and Immunology, 1994, 186, 33-54.	0.7	53
82	Complex interactions at a GC-rich domain regulate cell type-dependent activity of the ornithine decarboxylase promoter Journal of Biological Chemistry, 1994, 269, 7941-7949.	1.6	27
83	T3 receptor suppression of Sp1-dependent transcription from the epidermal growth factor receptor promoter via overlapping DNA-binding sites. Journal of Biological Chemistry, 1993, 268, 16065-16073.	1.6	66
84	Disruption of the human papillomavirus type 16 E2 gene protects cervical carcinoma cells from E2F-induced apoptosis Journal of General Virology, 1997, 78, 3009-3018.	1.3	46
85	Epithelial specific transcriptional regulation of the bovine papillomavirus 4 promoter by E2 Journal of General Virology, 1998, 79, 501-508.	1.3	8
86	Cellular transcription factors regulate human papillomavirus type 16 gene expression by binding to a subset of the DNA sequences recognized by the viral E2 protein. Journal of General Virology, 1999, 80, 2087-2096.	1.3	11
87	Transcription-modulatory activities of differentially spliced cDNAs encoding the E2 protein of human papillomavirus type 16. Journal of General Virology, 1999, 80, 2461-2470.	1.3	14
88	Phylogenetic analysis of 48 papillomavirus types and 28 subtypes and variants: a showcase for the molecular evolution of DNA viruses. Journal of Virology, 1992, 66, 5714-5725.	1.5	134
89	Control of human papillomavirus type 11 origin of replication by the E2 family of transcription regulatory proteins. Journal of Virology, 1992, 66, 5224-5231.	1.5	112
90	Identification and characterization of novel promoters in the genome of human papillomavirus type 18. Journal of Virology, 1993, 67, 4296-4306.	1.5	28

#	Article	IF	CITATIONS
91	The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID. Journal of Virology, 1994, 68, 6411-6420.	1.5	182
92	trans activation by the full-length E2 proteins of human papillomavirus type 16 and bovine papillomavirus type 1 in vitro and in vivo: cooperation with activation domains of cellular transcription factors. Journal of Virology, 1994, 68, 6655-6666.	1.5	65
93	Low-affinity E2-binding site mediates downmodulation of E2 transactivation of the human papillomavirus type 8 late promoter. Journal of Virology, 1994, 68, 6959-6966.	1.5	26
94	The E2 transcriptional repressor can compensate for Sp1 activation of the human papillomavirus type 18 early promoter. Journal of Virology, 1994, 68, 7075-7082.	1.5	78
95	Human papillomavirus type 11 E2 proteins repress the homologous E6 promoter by interfering with the binding of host transcription factors to adjacent elements. Journal of Virology, 1994, 68, 1115-1127.	1.5	142
96	Both viral E2 protein and the cellular factor PEBP2 regulate transcription via E2 consensus sites within the bovine papillomavirus type 4 long control region. Journal of Virology, 1995, 69, 6038-6046.	1.5	29
97	E2 represses the late gene promoter of human papillomavirus type 8 at high concentrations by interfering with cellular factors. Journal of Virology, 1996, 70, 119-126.	1.5	37
98	Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein. Journal of Virology, 1997, 71, 50-58.	1.5	167
99	Different mechanisms contribute to the E2-mediated transcriptional repression of human papillomavirus type 18 viral oncogenes. Journal of Virology, 1997, 71, 9343-9349.	1.5	106
100	Transactivation by the E2 Protein of Oncogenic Human Papillomavirus Type 31 Is Not Essential for Early and Late Viral Functions. Journal of Virology, 1998, 72, 8115-8123.	1.5	84
101	A Novel YY1-Independent Silencer Represses the Activity of the Human Papillomavirus Type 16 Enhancer. Journal of Virology, 1998, 72, 10083-10092.	1.5	24
102	Transactivation-Competent Bovine Papillomavirus E2 Protein Is Specifically Required for Efficient Repression of Human Papillomavirus Oncogene Expression and for Acute Growth Inhibition of Cervical Carcinoma Cell Lines. Journal of Virology, 1998, 72, 3925-3934.	1.5	101
103	Viral Load, Integration and Methylation of E2BS3 and 4 in Human Papilloma Virus (HPV) 16-Positive Vaginal and Vulvar Carcinomas. PLoS ONE, 2014, 9, e112839.	1.1	12
104	Diffusible VP22-E2 Protein Kills Bystander Cells and Offers a Route for Cervical Cancer Gene Therapy. Human Gene Therapy, 2006, .	1.4	0
105	Human Papillomaviruses and Cancer. , 2012, , 463-487.		0
124	The E6/E7 promoter of extrachromosomal HPV16 DNA in cervical cancers escapes from cellular repression by mutation of target sequences for YY1. EMBO Journal, 1994, 13, 1460-6.	3.5	80
125	Tumor suppressor or oncogene? A critical role of the human papillomavirus (HPV) E2 protein in cervical cancer progression. American Journal of Cancer Research, 2011, 1, 373-389.	1.4	24
126	Gene Expression of Genital Human Papillomaviruses and Considerations on Potential Antiviral Approaches. Antiviral Therapy, 2002, 7, 219-237.	0.6	68

#	Article	IF	CITATIONS
127	Sequence-Dependent Interaction of the Human Papillomavirus E2 Protein with the DNA Elements on Its DNA Replication Origin. International Journal of Molecular Sciences, 2023, 24, 6555.	1.8	4